Magentiq Eye

Magentiq Eye offers a groundbreaking AI aided colonoscopy solution. The company uses the growing power of deep learning, image processing, and video processing to help doctors become more accurate and effective, potentially saving millions of lives and billions of dollars. The company’s first product is MAGENTIQ-COLO, which is used to increase adenoma (polyp) detection rates and the overall quality of colonoscopy exams. MAGENTIQ-COLO is a real-time adjunct to the colonoscopy device that points out suspicious locations of polyps in the videos, thereby helping doctors reduce their polyp miss-rates. Given the large population that undergoes colonoscopy annually, even a modest decrease in polyp miss-rates has the potential to save many lives. MAGENTIQ-COLO has received the CE mark and FDA clearance. It also completed a successful multi-center international clinical trial to attain clearance for marketing in the USA. Its next version includes additional features such as polyp size estimation, polyp characterization, and additional quality measurements.

Magentiq Eye has raised $6.1M in total funding across 9 rounds. The company is currently at the A stage. Key investors include aMoon Fund, Nova Capital Management, Nina Capital.

Magentiq Eye was founded in 2014 by Dror Zur (Co-founder & CEO).

Magentiq Eye operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, with core technologies in Artificial Intelligence, Deep Learning, Computer Vision, Platforms & Interfaces, Software. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Magentiq Eye is based in Ben Gurion Blvd 6, Haifa, Israel, North District.